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Introduction
Chronic non-bacterial osteomyelitis (CNO) is an inflamma-
tory disorder of the skeletal system of unknown etiology.
Long-term follow-up and response to treatment data have
rarely been reported. The aim of the study was to charac-
terize the clinical, radiological, histological and laboratory
data at juvenile CNO onset, and to analyze the long term
treatment response.
Methods
The course of disease of 93 juvenile patients (58% female)
with non-bacterial inflammatory bone lesions was evalu-
ated retrospectively. 1098 patient visits and 558 MRI
findings were reviewed. Clinical, radiological, histological
and laboratory data were assessed at disease onset and
for a median time of disease of 46 months.
Results
The mean age at disease onset was 10.9 years, the mean
time between the first symptoms and the diagnosis of
CNO was 11 months. 84% of the patients had multifocal
bone lesions. Biopsy was performed in 80 patients. Only
when bone biopsy was taken within 12 months of symp-
tom onset, cellular infiltrates could be observed. At later
time points, fibrosis, hyperostosis and bone edema predo-
minated. 25% of all patients developed peripheral arthri-
tis, 8% inflammatory bowel disease. The initial treatment
consisted of non-steroidal anti-inflammatory drugs
(NSAIDs). 37% of the patients required second line ther-
apy consisting of sulfasalazine and short term oral corti-
costeroids, 8% of the patients required bisphosphonates
or TNF-blocking agents. Median time to first clinical
remission was 6.0 months and 94% of patients achieved
clinical remission within the period under review. Med-
ian time to first radiological remission, however, was 27.4
months and only 67% of all patients achieved complete
radiological remission. Time to remission was indepen-
dent of the CNO being unifocal or multifocal. In detail
analysis of the treatment response revealed that initiation
of sulfasalazine treatment in NSAID non-responders led
to a significant and sustained decline of the clinical, as
well as the radiological number of lesions.
Conclusion
The rapid clinical improvement in CNO, following
initiation of therapy with NSAIDs, is not accompanied
by a likewise decrease of the number of radiological
lesions. Treatment with sulfasalazine is effective in
childhood CNO.
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